LOTUS EYE HOSP & INST L Fair Value
LOTUSEYE · Healthcare · Current price ₹108.5
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹26 | 0% ROE fading to 12% over ~3 yrs, on ₹30 book |
| Relative P/E | ₹3 | EPS × 65.0 peer-median P/E |
| Graham floor | ₹5 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is LOTUS EYE HOSP & INST L undervalued?
DocStoX estimates the fair value of LOTUS EYE HOSP & INST L at ₹16 per share, versus the current market price of ₹109. That puts the stock about -85.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹26), Relative P/E (₹3), Graham floor (₹5). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹3 (bear) to ₹16 (base) to ₹26 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on LOTUS EYE HOSP & INST L
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.